drugset / Trial / NCT05945615

Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis

NCT05945615

Phase 3 Completed 36 enrolled Milton S. Hershey Medical Center
RandomizedCrossoverSingle-blindTreatment

Summary

After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle. This leads to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid Facial Paralysis. It is characterized by poor facial symmetry and function, hypertonic facial muscles at rest, and abnormal facial movements. One sequela is acquired blepharoptosis causing a smaller ocular aperture, visual field obstruction, cosmetic deformity, and abnormal periocular spasms. This study aims to evaluate an FDA approved medication for acquired blepharoptosis due to synkinesis/hyperkinesis as an adjunct to treatment.

Timeline

Start
2024-01-11
Primary completion
2026-01-08
Completion
2026-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymetazoline Other / unclassified 0.1 % Other